

Hyun S Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3869432/publications.pdf>

Version: 2024-02-01

135
papers

4,368
citations

145106

33
h-index

156644

58
g-index

140
all docs

140
docs citations

140
times ranked

5832
citing authors

#	ARTICLE	IF	CITATIONS
1	Augmented fluoroscopy guided transbronchial pulmonary microwave ablation using a steerable sheath. <i>Translational Lung Cancer Research</i> , 2022, 11, 150-164.	1.3	3
2	PD-1 targeted immunotherapy for advanced hepatocellular carcinoma: current utilization and outcomes in the USA. <i>Future Oncology</i> , 2022, 18, 1691-1703.	1.1	4
3	Microwave Ablation versus Stereotactic Body Radiotherapy for Stage I Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2022, 33, 964-971.e2.	0.2	4
4	Locoregional Therapies for Colorectal Cancer Liver Metastases: Options Beyond Resection. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 133-146.	1.8	5
5	Microsatellite Instability and KRAS Mutation in Stage IV Colorectal Cancer: Prevalence, Geographic Discrepancies, and Outcomes From the National Cancer Database. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 307-318.	2.3	17
6	Co-inhibitor expression on tumor infiltrating and splenic lymphocytes after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer. <i>Scientific Reports</i> , 2021, 11, 6956.	1.6	3
7	Predictors of venous thromboembolism in cancer patients using machine learning. <i>Journal of Clinical Oncology</i> , 2021, 39, e24042-e24042.	0.8	1
8	PET Imaging of CD8 via SMART for Monitoring the Immunotherapy Response. <i>BioMed Research International</i> , 2021, 2021, 1-6.	0.9	2
9	The effect of chronic viral hepatitis on prognostic value of inflammatory biomarkers in hepatocellular carcinoma. <i>Cancer Medicine</i> , 2021, 10, 5395-5404.	1.3	0
10	Effectiveness of Thermal Ablation and Stereotactic Radiotherapy Based on Stage I Lung Cancer Histology. <i>Journal of Vascular and Interventional Radiology</i> , 2021, 32, 1022-1028.e4.	0.2	11
11	Percutaneous Management of Benign Biliary Strictures. <i>Seminars in Interventional Radiology</i> , 2021, 38, 291-299.	0.3	4
12	⁹⁰ Y radioembolization in the treatment of neuroendocrine neoplasms: Results of an international multicenter retrospective study. <i>Journal of Nuclear Medicine</i> , 2021, , jnumed.121.262561.	2.8	10
13	Consensus Guidelines for the Definition of Time-to-Event End Points in Image-guided Tumor Ablation: Results of the SIO and DATECAN Initiative. <i>Radiology</i> , 2021, 301, 533-540.	3.6	72
14	Radiomic Features and Machine Learning for the Discrimination of Renal Tumor Histological Subtypes: A Pragmatic Study Using Clinical-Routine Computed Tomography. <i>Cancers</i> , 2020, 12, 3010.	1.7	19
15	Novel TSPO-targeted Doxorubicin Prodrug for Colorectal Carcinoma Cells. <i>Anticancer Research</i> , 2020, 40, 5371-5378.	0.5	6
16	Trials of locoregional therapies inspired by SABR-COMET. <i>Lancet</i> , The, 2020, 396, 956-957.	6.3	5
17	Genomics and Interventional Oncology in Primary Liver Cancer. <i>Digestive Disease Interventions</i> , 2020, 04, 053-059.	0.3	0
18	Direct-Acting Antivirals Improve Overall Survival in Interventional Oncology Patients with Hepatitis C and Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 953-960.	0.2	5

#	ARTICLE	IF	CITATIONS
19	Genomics and Interventional Oncology in Metastatic Liver Cancer. <i>Digestive Disease Interventions</i> , 2020, 04, 206-213.	0.3	0
20	Oligometastatic Disease and Interventional Oncology. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 166-173.	1.0	3
21	Stereotactic Body Radiotherapy for Stage I Renal Cell Carcinoma: National Treatment Trends and Outcomes Compared to Partial Nephrectomy and Thermal Ablation. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 564-571.	0.2	11
22	Discriminating malignant and benign clinical T1 renal masses on computed tomography. <i>Medicine (United States)</i> , 2020, 99, e19725.	0.4	25
23	Safety and Efficacy of Percutaneous Cholecystostomy for Emphysematous Cholecystitis. <i>Journal of Clinical Imaging Science</i> , 2020, 10, 9.	0.4	1
24	Neuroendocrine and carcinoid tumors of the gastrointestinal tract: Epidemiology and outcomes from the National Cancer Database.. <i>Journal of Clinical Oncology</i> , 2020, 38, 609-609.	0.8	4
25	Systemic impact on tumor growth after combined immuno-thermal ablation in a murine model of colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 198-198.	0.8	1
26	KRAS status and survival in multicenter study of RAS mutations (MURAS) in patients with colorectal liver metastases receiving Y90 radioembolization treatment.. <i>Journal of Clinical Oncology</i> , 2020, 38, 239-239.	0.8	0
27	Quantification of immune response after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 160-160.	0.8	0
28	Adoptive Cell Therapy for Gastrointestinal Cancers. <i>Digestive Disease Interventions</i> , 2020, 04, 345-350.	0.3	0
29	Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non-Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2019, 2, e199702.	2.8	34
30	Interventional Oncology in Immuno-Oncology Part 1: Thermal Ablation. <i>Digestive Disease Interventions</i> , 2019, 03, 143-154.	0.3	1
31	Inflammatory markers in intrahepatic cholangiocarcinoma: Effects of advanced liver disease. <i>Cancer Medicine</i> , 2019, 8, 5916-5929.	1.3	28
32	The impact of socioeconomic status on outcomes in hepatocellular carcinoma: Inferences from primary insurance. <i>Cancer Medicine</i> , 2019, 8, 5948-5958.	1.3	11
33	Interventional Oncology in Immuno-Oncology Part 2: Transcatheter Therapies. <i>Digestive Disease Interventions</i> , 2019, 03, 155-162.	0.3	1
34	Phase Ib trial of gemcitabine with yttrium-90 in patients with hepatic metastasis of pancreaticobiliary origin. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 944-956.	0.6	11
35	Hepatocellular carcinoma: Impact of academic setting and hospital volume on patient survival. <i>Surgical Oncology</i> , 2019, 31, 111-118.	0.8	11
36	In Regard to Jackson et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 695-696.	0.4	2

#	ARTICLE	IF	CITATIONS
37	Intrahepatic Cholangiocarcinoma: Socioeconomic Discrepancies, Contemporary Treatment Approaches and Survival Trends from the National Cancer Database. <i>Annals of Surgical Oncology</i> , 2019, 26, 1993-2000.	0.7	15
38	Yttrium-90 Radioembolization Is Cost Effective in Intrahepatic Cholangiocarcinoma: A SEER Medicare Population Study. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 293-297.	0.2	3
39	Locoregional Therapy, Immunotherapy and the Combination in Hepatocellular Carcinoma: Future Directions. <i>Liver Cancer</i> , 2019, 8, 326-340.	4.2	30
40	Lymphocyte innateness defined by transcriptional states reflects a balance between proliferation and effector functions. <i>Nature Communications</i> , 2019, 10, 687.	5.8	136
41	Impact of Direct Acting Antivirals on Survival in Patients with Chronic Hepatitis C and Hepatocellular Carcinoma. <i>Scientific Reports</i> , 2019, 9, 17081.	1.6	22
42	Modeling of implementation of the new Organ Procurement and Transplantation Network/United Network for Organ Sharing policy for patients with hepatocellular carcinoma. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 993-1002.	0.6	1
43	Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States National Cancer Database. <i>European Radiology</i> , 2019, 29, 2679-2689.	2.3	58
44	Transjugular intrahepatic portosystemic shunt as a bridge to liver transplant: Current state and future directions. <i>Transplantation Reviews</i> , 2019, 33, 64-71.	1.2	11
45	Partial nephrectomy versus ablative techniques for small renal masses: a systematic review and network meta-analysis. <i>European Radiology</i> , 2019, 29, 1293-1307.	2.3	75
46	Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases. <i>Cancer</i> , 2018, 124, 1992-2000.	2.0	17
47	90 Y radioembolization dosimetry using a simple semi-quantitative method in intrahepatic cholangiocarcinoma: Glass versus resin microspheres. <i>Nuclear Medicine and Biology</i> , 2018, 59, 22-28.	0.3	16
48	Racial Disparities and Sociodemographic Differences in Incidence and Survival Among Pediatric Patients in the United States With Primary Liver Cancer. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 262-267.	1.1	13
49	Cryotherapy for nodal metastasis in NSCLC with acquired resistance to immunotherapy. , 2018, 6, 147.		14
50	Oncolytic virus immunotherapy: future prospects for oncology. , 2018, 6, 140.		197
51	Survival Rates after Thermal Ablation versus Stereotactic Radiation Therapy for Stage 1 Non-Small Cell Lung Cancer: A National Cancer Database Study. <i>Radiology</i> , 2018, 289, 862-870.	3.6	66
52	Ablation versus Resection for Stage 1A Renal Cell Carcinoma: National Variation in Clinical Management and Selected Outcomes. <i>Radiology</i> , 2018, 288, 889-897.	3.6	32
53	Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization. <i>BMC Cancer</i> , 2018, 18, 75.	1.1	22
54	Comparative Effectiveness of Thermal Ablation, Surgical Resection, and Active Surveillance for T1a Renal Cell Carcinoma: A Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked Population Study. <i>Radiology</i> , 2018, 288, 81-90.	3.6	88

#	ARTICLE	IF	CITATIONS
55	Genomic mutations and histopathologic biomarkers in Y90 radioembolization for chemorefractory colorectal liver metastases. <i>Oncotarget</i> , 2018, 9, 32523-32533.	0.8	7
56	The effect of socioeconomic factors on the outcome of hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 466-466.	0.8	0
57	The effect of socioeconomic factors on the outcome of intrahepatic cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 465-465.	0.8	0
58	Treatment patterns and survival for hepatocellular carcinoma in USA and Taiwan.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16120-e16120.	0.8	0
59	Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 27-34.	0.6	43
60	Bridging Locoregional Therapy Prolongs Survival in Patients Listed for Liver Transplant with Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 410-420.	0.9	13
61	Bridging locoregional therapy: Longitudinal trends and outcomes in patients with hepatocellular carcinoma. <i>Transplantation Reviews</i> , 2017, 31, 136-143.	1.2	10
62	Percutaneous Hepaticojejunostomy Using a Radiofrequency Wire for Management of a Postoperative Bile Leak. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 139-143.	0.9	5
63	Hepatic intra-arterial injection of irinotecan drug eluting beads (DEBIRI) for patients with unresectable colorectal liver metastases: A systematic review. <i>Surgical Oncology</i> , 2017, 26, 268-275.	0.8	47
64	Independent prognostic factors for posttransplant survival in hepatocellular carcinoma patients undergoing liver transplantation. <i>Cancer Medicine</i> , 2017, 6, 26-35.	1.3	11
65	Cancer-directed therapy and potential impact on survivals in nonresected hepatocellular carcinoma: SEER-Medicare population study. <i>Future Oncology</i> , 2017, 13, 2021-2033.	1.1	4
66	Targeted Yttrium 89-Doxorubicin Drug-Eluting Bead—A Safety and Feasibility Pilot Study in a Rabbit Liver Cancer Model. <i>Molecular Pharmaceutics</i> , 2017, 14, 2824-2830.	2.3	7
67	Connecting cancer biology and clinical outcomes to imaging in KRAS mutant and wild-type colorectal cancer liver tumors following selective internal radiation therapy with yttrium-90. <i>Abdominal Radiology</i> , 2017, 42, 451-459.	1.0	16
68	Percutaneous interventional management of biliary complications after pediatric liver transplantation: A 16-year single-institution experience. <i>Pediatric Transplantation</i> , 2017, 21, e12837.	0.5	8
69	Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus 90Y-radioembolization for hepatocellular carcinoma. <i>European Radiology</i> , 2017, 27, 2031-2041.	2.3	24
70	Effect of Bridging Local-Regional Therapy on Recurrence of Hepatocellular Carcinoma and Survival after Orthotopic Liver Transplantation. <i>Radiology</i> , 2017, 282, 869-879.	3.6	29
71	Immuno-thermal ablations “boosting the anticancer immune response.”, 2017, 5, 78.		146
72	Establishment of human metastatic colorectal cancer model in rabbit liver: A pilot study. <i>PLoS ONE</i> , 2017, 12, e0177212.	1.1	3

#	ARTICLE	IF	CITATIONS
73	Treatment algorithm based on the multivariate survival analyses in patients with advanced hepatocellular carcinoma treated with trans-arterial chemoembolization. PLoS ONE, 2017, 12, e0170750.	1.1	9
74	In vitro biologic efficacy of sunitinib drug-eluting beads on human colorectal and hepatocellular carcinoma—A pilot study. PLoS ONE, 2017, 12, e0174539.	1.1	8
75	Predictors and prognosticators for survival with Yttrium-90 radioembolization therapy for unresectable colorectal cancer liver metastasis. Oncotarget, 2017, 8, 37912-37922.	0.8	24
76	Standardized Added Metabolic Activity Predicts Survival After Intra-arterial Resin-Based 90Y Radioembolization Therapy in Unresectable Chemorefractory Metastatic Colorectal Cancer to the Liver. Clinical Nuclear Medicine, 2016, 41, e76-e81.	0.7	5
77	90Y Radioembolization Lung Shunt Fraction in Primary and Metastatic Liver Cancer as a Biomarker for Survival. Clinical Nuclear Medicine, 2016, 41, 21-27.	0.7	31
78	Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer. Journal of Translational Medicine, 2016, 14, 111.	1.8	78
79	Abscopal Effects and Yttrium-90 Radioembolization. CardioVascular and Interventional Radiology, 2016, 39, 1076-1080.	0.9	34
80	The Impact of Tunneled Catheters for Ascites and Peritoneal Carcinomatosis on Patient Rehospitalizations. CardioVascular and Interventional Radiology, 2016, 39, 711-716.	0.9	14
81	The Effect of Bridging Locoregional Therapy and Sociodemographics on Survival in Hepatocellular Carcinoma Patients Undergoing Orthotopic Liver Transplantation: A United Network for Organ Sharing Population Study. Journal of Vascular and Interventional Radiology, 2016, 27, 1822-1828.	0.2	8
82	Reply to: "Percutaneous Management of Benign Biliary Strictures: Is It Time to Focus on Reducing Procedure Invasiveness?". Journal of Vascular and Interventional Radiology, 2016, 27, 936-937.	0.2	0
83	Sociodemographic disparities in treatment and survival of small localized renal cell carcinoma: surgical resection versus thermal ablation. Journal of Comparative Effectiveness Research, 2016, 5, 441-452.	0.6	12
84	From the Guest Editor. Cancer Journal (Sudbury, Mass), 2016, 22, 363-364.	1.0	18
85	SW43-DOX±loading onto drug-eluting bead, a potential new targeted drug delivery platform for systemic and locoregional cancer treatment — An in vitro evaluation. Molecular Oncology, 2016, 10, 1133-1145.	2.1	9
86	Survival in unresectable AJCC stage I and II HCC and the effect of DEB-TACE: SEER versus tertiary cancer center cohort study. Journal of Comparative Effectiveness Research, 2016, 5, 141-154.	0.6	4
87	Sociodemographic impact on survival in unresectable hepatocellular carcinoma: a survival epidemiology and end results study. Future Oncology, 2016, 12, 183-198.	1.1	8
88	Lung Shunt Fraction prior to Yttrium-90 Radioembolization Predicts Survival in Patients with Neuroendocrine Liver Metastases: Single-Center Prospective Analysis. CardioVascular and Interventional Radiology, 2016, 39, 1007-1014.	0.9	27
89	Percutaneous Management of Benign Biliary Strictures with Large-Bore Catheters: Comparison between Patients with and without Orthotopic Liver Transplantation. Journal of Vascular and Interventional Radiology, 2016, 27, 219-225.e1.	0.2	25
90	Phase Ib trial of gemcitabine with yttrium-90 in patients with hepatic tumors of pancreatobiliary origin.. Journal of Clinical Oncology, 2016, 34, 460-460.	0.8	19

#	ARTICLE	IF	CITATIONS
91	Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis. <i>Cancer</i> , 2015, 121, 2164-2174.	2.0	51
92	The Role of Diffusion-Weighted Imaging (DWI) in Locoregional Therapy Outcome Prediction and Response Assessment for Hepatocellular Carcinoma (HCC): The New Era of Functional Imaging Biomarkers. <i>Diagnostics</i> , 2015, 5, 546-563.	1.3	24
93	Immediate post-doxorubicin drug-eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma: A pilot study. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 42, 981-989.	1.9	20
94	Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1167-1174.	1.4	18
95	KRAS Status as an Independent Prognostic Factor for Survival after Yttrium-90 Radioembolization Therapy for Unresectable Colorectal Cancer Liver Metastases. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 1102-1111.	0.2	43
96	R.E.N.A.L. (Radius, Exophytic/Endophytic, Nearness to Collecting System or Sinus, Anterior/Posterior,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Complications after Percutaneous Ablative Therapies for Renal Cell Carcinoma: A 5-Year Experience. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 686-693.	0.2	64
97	⁹⁰ Y Radioembolization: Multimodality Imaging Pattern Approach with Angiographic Correlation for Optimized Target Therapy Delivery. <i>Radiographics</i> , 2015, 35, 1602-1618.	1.4	29
98	Baseline and Early MR Apparent Diffusion Coefficient Quantification as a Predictor of Response of Unresectable Hepatocellular Carcinoma to Doxorubicin Drug-Eluting Bead Chemoembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 1777-1786.	0.2	29
99	Evolution of a Specialty: The Case for the Association of Chiefs of Interventional Radiology. <i>Seminars in Interventional Radiology</i> , 2014, 31, 107-110.	0.3	2
100	PET Response Criteria for Solid Tumors Predict Survival at Three Months After Intra-Arterial Resin-Based ⁹⁰ Yttrium Radioembolization Therapy for Unresectable Intrahepatic Cholangiocarcinoma. <i>Clinical Nuclear Medicine</i> , 2014, 39, 944-950.	0.7	19
101	Quantitative Dosimetry for Yttrium-90 Radionuclide Therapy: Tumor Dose Predicts Fluorodeoxyglucose Positron Emission Tomography Response in Hepatic Metastatic Melanoma. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 288-295.	0.2	28
102	Modified Response Evaluation Criteria in Solid Tumors and European Association for the Study of the Liver Criteria Using Delayed-Phase Imaging at an Early Time Point Predict Survival in Patients with Unresectable Intrahepatic Cholangiocarcinoma following Yttrium-90 Radioembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 256-265.	0.2	86
103	Locoregional therapies for metastatic colorectal carcinoma to the liver-An evidence-based review. <i>Journal of Surgical Oncology</i> , 2014, 110, 182-196.	0.8	29
104	Apparent diffusion coefficient quantification as an early imaging biomarker of response and predictor of survival following yttrium-90 radioembolization for unresectable infiltrative hepatocellular carcinoma with portal vein thrombosis. <i>Abdominal Imaging</i> , 2014, 39, 969-978.	2.0	44
105	Safety and Efficacy of a Circumferential Clip-Based Vascular Closure Device in Cirrhotic and Coagulopathic Patients with Hepatocellular Carcinoma After Doxorubicin Drug-eluting Beads Transarterial Chemoembolization. <i>CardioVascular and Interventional Radiology</i> , 2014, 37, 664-670.	0.9	7
106	A Simple Method for Estimating Dose Delivered to Hepatocellular Carcinoma after Yttrium-90 Glass-Based Radioembolization Therapy: Preliminary Results of a Proof of Concept Study. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 277-287.	0.2	40
107	Yttrium-90 Radioembolization for Unresectable Standard-chemorefractory Intrahepatic Cholangiocarcinoma: Survival, Efficacy, and Safety Study. <i>CardioVascular and Interventional Radiology</i> , 2013, 36, 440-448.	0.9	133
108	Safety and Efficacy of Doxorubicin Drug-eluting Bead Transarterial Chemoembolization in Patients with Advanced Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 307-315.	0.2	68

#	ARTICLE	IF	CITATIONS
109	90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness. <i>Journal of Comparative Effectiveness Research</i> , 2013, 2, 435-444.	0.6	8
110	Influence of transjugular intrahepatic portosystemic shunt in patients awaiting orthotopic liver transplant on post-transplant outcome. <i>Gastrointestinal Intervention</i> , 2012, 1, 69-73.	0.1	3
111	Safety and Feasibility of Same-day Discharge of Patients with Unresectable Hepatocellular Carcinoma Treated with Doxorubicin Drug-eluting Bead Transcatheter Chemoembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2012, 23, 1286-1293.e1.	0.2	26
112	MR-guided High-intensity Focused Ultrasound Treatment for Symptomatic Uterine Leiomyomata. <i>Academic Radiology</i> , 2011, 18, 970-976.	1.3	93
113	Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocellular carcinoma (HCC). <i>Journal of Surgical Oncology</i> , 2010, 101, 476-480.	0.8	196
114	Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study. <i>Hpb</i> , 2010, 12, 174-180.	0.1	43
115	The Effectiveness of Locoregional Therapies versus Supportive Care in Maintaining Survival within the Milan Criteria in Patients with Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2010, 21, 1197-1204.	0.2	16
116	Longitudinal Quality of Life Assessment of Patients with Hepatocellular Carcinoma after Primary Transarterial Chemoembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2010, 21, 1024-1030.	0.2	41
117	Comparison of Yttrium-90 Radioembolization and Transcatheter Arterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2010, 21, 224-230.	0.2	175
118	Safety of catheter-directed thrombolysis for deep venous thrombosis in cancer patients. <i>Journal of Vascular Surgery</i> , 2008, 47, 388-394.	0.6	45
119	A Comparison of Clinical Outcomes with Retrievable and Permanent Inferior Vena Cava Filters. <i>Journal of Vascular and Interventional Radiology</i> , 2008, 19, 393-399.	0.2	89
120	Long-term Efficacy and Safety of Uterine Artery Embolization in Young Patients with and without Uteroovarian Anastomoses. <i>Journal of Vascular and Interventional Radiology</i> , 2008, 19, 195-200.	0.2	23
121	Safety and Utility of Uterine Artery Embolization with CO2 and a Gadolinium-based Contrast Medium. <i>Journal of Vascular and Interventional Radiology</i> , 2007, 18, 1021-1027.	0.2	5
122	Utero-Ovarian Anastomosis: Histopathologic Correlation after Uterine Artery Embolization with or without Ovarian Artery Embolization. <i>Journal of Vascular and Interventional Radiology</i> , 2007, 18, 31-39.	0.2	24
123	Percutaneous Image-guided Radiofrequency Thermal Ablation for Large Symptomatic Uterine Leiomyomata after Uterine Artery Embolization: A Feasibility and Safety Study. <i>Journal of Vascular and Interventional Radiology</i> , 2007, 18, 41-48.	0.2	24
124	Development of a Hypertrophic Ovarian Artery After Uterine Artery Embolization with Polyvinyl Alcohol Particles. <i>CardioVascular and Interventional Radiology</i> , 2007, 30, 1033-1036.	0.9	5
125	Catheter-directed Thrombectomy and Thrombolysis for Acute Renal Vein Thrombosis. <i>Journal of Vascular and Interventional Radiology</i> , 2006, 17, 815-822.	0.2	57
126	Effects of Utero-ovarian Anastomoses on Basal Follicle-stimulating Hormone Level Change after Uterine Artery Embolization with Tris-acryl Gelatin Microspheres. <i>Journal of Vascular and Interventional Radiology</i> , 2006, 17, 965-971.	0.2	44

#	ARTICLE	IF	CITATIONS
127	Effects of Utero-ovarian Anastomoses on Clinical Outcomes and Repeat Intervention Rates after Uterine Artery Embolization. <i>Journal of Vascular and Interventional Radiology</i> , 2006, 17, 783-789.	0.2	27
128	Embolotherapy for Pelvic Congestion Syndrome: Long-term Results. <i>Journal of Vascular and Interventional Radiology</i> , 2006, 17, 289-297.	0.2	229
129	Adjunctive Percutaneous Mechanical Thrombectomy for Lower-extremity Deep Vein Thrombosis: Clinical and Economic Outcomes. <i>Journal of Vascular and Interventional Radiology</i> , 2006, 17, 1099-1104.	0.2	126
130	Endovenous Laser Ablation of the Great Saphenous Vein with a 980-nm Diode Laser in Continuous Mode: Early Treatment Failures and Successful Repeat Treatments. <i>Journal of Vascular and Interventional Radiology</i> , 2006, 17, 1449-1455.	0.2	29
131	Lower Energy Endovenous Laser Ablation of the Great Saphenous Vein with 980 nm Diode Laser in Continuous Mode. <i>CardioVascular and Interventional Radiology</i> , 2006, 29, 64-69.	0.9	58
132	Catheter-Directed Thrombolysis with Percutaneous Rheolytic Thrombectomy Versus Thrombolysis Alone in Upper and Lower Extremity Deep Vein Thrombosis. <i>CardioVascular and Interventional Radiology</i> , 2006, 29, 1003-1007.	0.9	70
133	Transhepatic Catheter-directed Thrombectomy and Thrombolysis of Acute Superior Mesenteric Venous Thrombosis. <i>Journal of Vascular and Interventional Radiology</i> , 2005, 16, 1685-1691.	0.2	106
134	Paracrine and Autocrine Functions of Brain-derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF) in Brain-derived Endothelial Cells. <i>Journal of Biological Chemistry</i> , 2004, 279, 33538-33546.	1.6	183
135	Electrophysiological diagnosis of interdigital neuropathy of the foot. <i>Muscle and Nerve</i> , 1984, 7, 218-225.	1.0	50